The Greater Cannabis Company, Inc. (GCAN)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
The Greater Cannabis Company, Inc. (GCAN) with AI Score 49/100 (Weak). The Greater Cannabis Company, Inc. focuses on developing and commercializing cannabinoid therapeutics through its oral transmucosal patch platform. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026The Greater Cannabis Company, Inc. (GCAN) Healthcare & Pipeline Overview
The Greater Cannabis Company, Inc., founded in 2014, develops cannabinoid therapeutics using an oral transmucosal patch platform for targeted drug delivery. Operating within the specialty and generic drug manufacturing sector, the company faces challenges in a competitive and regulated market.
Investment Thesis
Investing in The Greater Cannabis Company, Inc. presents a high-risk, high-reward scenario. The company's focus on cannabinoid therapeutics and its oral transmucosal patch platform offer potential for differentiated drug delivery. However, the company's negative profit margin of -14254.3% and small market capitalization of $0.00B indicate significant financial challenges. Growth depends on successful clinical trials, regulatory approvals, and market adoption of its products. The company's beta of 0.55 suggests lower volatility compared to the broader market, but the OTC listing introduces additional risks. Investors should carefully consider the regulatory uncertainties and competitive pressures within the cannabinoid therapeutics market before investing.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.00B indicates the company is a micro-cap stock with limited liquidity and higher volatility.
- P/E Ratio of -252.63 reflects the company's current lack of profitability and reliance on future growth expectations.
- Profit Margin of -14254.3% demonstrates significant operational inefficiencies and high expenses relative to revenue.
- Gross Margin of -33.3% suggests the company's cost of goods sold exceeds its revenue, indicating unsustainable business operations.
- Beta of 0.55 indicates the stock is less volatile than the market average, potentially offering some downside protection during market downturns.
Competitors & Peers
Strengths
- Innovative oral transmucosal patch platform.
- Focus on cannabinoid therapeutics.
- Potential for improved drug bioavailability.
- Small, agile team.
Weaknesses
- Limited financial resources.
- Dependence on regulatory approvals.
- Small market capitalization.
- Negative profit and gross margins.
Catalysts
- Upcoming: Clinical trial results for cannabinoid therapeutics.
- Upcoming: Regulatory approvals from FDA or EMA.
- Upcoming: Strategic partnerships with pharmaceutical companies.
- Ongoing: Increasing acceptance of cannabinoid-based medicines.
- Ongoing: Research validating the therapeutic benefits of cannabinoids.
Risks
- Potential: Evolving regulatory landscape for cannabis products.
- Potential: Intense competition from established pharmaceutical companies.
- Ongoing: Limited financial resources and access to capital.
- Ongoing: Negative perception of cannabis among some consumers.
- Potential: Delays in clinical trials or regulatory approvals.
Growth Opportunities
- Expansion of Cannabinoid Therapeutics: The increasing acceptance and legalization of cannabis for medical purposes present a significant growth opportunity. As research continues to validate the therapeutic benefits of cannabinoids for conditions like chronic pain, epilepsy, and anxiety, The Greater Cannabis Company, Inc. can capitalize on this trend by developing and commercializing new cannabinoid-based therapies. The global cannabinoid therapeutics market is projected to reach billions of dollars in the coming years, offering a substantial market for GCAN's products.
- Oral Transmucosal Patch Platform: The company's oral transmucosal patch platform offers a differentiated drug delivery method. This platform could provide improved bioavailability, controlled release, and ease of use compared to traditional oral medications. By focusing on this innovative delivery system, The Greater Cannabis Company, Inc. can potentially capture a niche market within the broader pharmaceutical industry. The market for advanced drug delivery systems is expected to grow as pharmaceutical companies seek to improve the efficacy and patient compliance of their products.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with other pharmaceutical companies, research institutions, or cannabis industry players can accelerate the development and commercialization of The Greater Cannabis Company, Inc.'s products. Collaborations can provide access to funding, expertise, and distribution networks. The pharmaceutical industry is increasingly reliant on partnerships to drive innovation and expand market reach. These partnerships can help GCAN expand its product pipeline and market presence.
- Regulatory Approvals and Market Access: Securing regulatory approvals from agencies like the FDA or EMA is crucial for commercializing cannabinoid therapeutics. Obtaining these approvals would allow The Greater Cannabis Company, Inc. to market its products to a wider audience and generate revenue. Navigating the regulatory landscape requires significant expertise and resources, but successful approvals can create substantial value for the company. The regulatory pathway for cannabinoid-based drugs is evolving, and GCAN must stay informed and adapt to changing requirements.
- Expansion into New Geographies: As cannabis regulations evolve globally, The Greater Cannabis Company, Inc. can expand its operations into new markets. This expansion would require careful consideration of local regulations, market dynamics, and competitive landscape. However, entering new geographies can significantly increase the company's revenue potential and market share. The global cannabis market is growing rapidly, and companies that can successfully navigate international expansion will be well-positioned for long-term success.
Opportunities
- Growing acceptance of cannabinoid therapeutics.
- Potential for strategic partnerships.
- Expansion into new geographies.
- Increasing research into cannabinoid benefits.
Threats
- Evolving regulatory landscape.
- Intense competition.
- Limited access to capital.
- Negative perception of cannabis.
Competitive Advantages
- Proprietary oral transmucosal patch platform for enhanced drug delivery.
- Focus on cannabinoid therapeutics in a growing market.
- Potential for intellectual property protection through patents.
About GCAN
The Greater Cannabis Company, Inc., established in 2014 and based in Baltimore, Maryland, is a pharmaceutical company focused on the development and commercialization of cannabinoid therapeutics. The company's core technology is an oral transmucosal patch platform designed to deliver cannabinoid-based drugs directly into the bloodstream via absorption through the buccal mucosa (the lining of the cheek). This delivery method aims to improve drug bioavailability and provide a more controlled and sustained release compared to traditional oral administration. The company's primary focus is on creating therapeutic products that leverage the potential benefits of cannabinoids for various medical conditions. Given its early stage, the company's success hinges on navigating the complex regulatory landscape surrounding cannabis-related products, securing funding for research and development, and successfully commercializing its patch platform. The company currently has a small team and is led by Aitan Zacharin. The company's future direction will depend on its ability to innovate and gain market acceptance in the cannabinoid therapeutics space.
What They Do
- Develops cannabinoid therapeutics for various medical conditions.
- Utilizes an oral transmucosal patch platform for drug delivery.
- Focuses on improving drug bioavailability and controlled release.
- Conducts research and development to create new cannabinoid-based therapies.
- Seeks regulatory approvals for its products from agencies like the FDA.
- Aims to commercialize its products and generate revenue.
Business Model
- Develops and patents cannabinoid-based therapeutic products.
- Seeks partnerships for clinical trials and regulatory approvals.
- Plans to commercialize products through direct sales and distribution agreements.
Industry Context
The Greater Cannabis Company, Inc. operates within the rapidly evolving cannabinoid therapeutics market, which is part of the broader specialty and generic drug manufacturing industry. This market is characterized by increasing research into the therapeutic potential of cannabinoids, evolving regulatory frameworks, and growing consumer acceptance. The industry is highly competitive, with numerous companies vying for market share. The company's success depends on its ability to differentiate its products, navigate regulatory hurdles, and secure funding in a dynamic and competitive landscape. Competitors include companies like ADVT, BBBT, CANL, EAPH, and GREH.
Key Customers
- Patients seeking alternative treatments for various medical conditions.
- Healthcare providers looking for innovative drug delivery methods.
- Pharmaceutical companies interested in cannabinoid therapeutics.
Financials
Chart & Info
The Greater Cannabis Company, Inc. (GCAN) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Lows On Friday
· Dec 6, 2019
-
Stocks That Hit 52-Week Lows On Monday
· Dec 2, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GCAN.
Price Targets
Wall Street price target analysis for GCAN.
MoonshotScore
What does this score mean?
The MoonshotScore rates GCAN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Aitan Zacharin
Managing
Aitan Zacharin is the managing person of The Greater Cannabis Company, Inc. Information about his prior experience and educational background is not available in the provided data. His leadership is crucial for guiding the company through the complex regulatory and competitive landscape of the cannabinoid therapeutics market.
Track Record: Given the limited information available, it is difficult to assess Aitan Zacharin's track record. The company's current financial state, with negative profit and gross margins, suggests significant challenges. His leadership will be critical in securing funding, navigating regulatory hurdles, and commercializing the company's products.
GCAN OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that The Greater Cannabis Company, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries a higher degree of risk due to the lack of regulatory oversight and transparency compared to exchange-listed companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Higher potential for fraud and manipulation.
- Lower liquidity and wider bid-ask spreads.
- Greater price volatility.
- Increased regulatory scrutiny.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the regulatory environment and potential risks.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Company's focus on developing cannabinoid therapeutics.
- Proprietary oral transmucosal patch platform.
- Potential for intellectual property protection through patents.
- Company's establishment in 2014.
- Presence of a CEO, Aitan Zacharin.
The Greater Cannabis Company, Inc. Stock: Key Questions Answered
What does The Greater Cannabis Company, Inc. do?
The Greater Cannabis Company, Inc. is a pharmaceutical company focused on developing and commercializing cannabinoid therapeutics. Its core technology is an oral transmucosal patch platform designed to deliver cannabinoid-based drugs directly into the bloodstream via absorption through the buccal mucosa. This delivery method aims to improve drug bioavailability and provide a more controlled and sustained release compared to traditional oral administration. The company seeks to create therapeutic products that leverage the potential benefits of cannabinoids for various medical conditions, navigating the complex regulatory landscape surrounding cannabis-related products.
What are the main risks for GCAN?
The Greater Cannabis Company, Inc. faces several key risks. The evolving regulatory landscape for cannabis products creates uncertainty and potential compliance challenges. Intense competition from established pharmaceutical companies and other cannabinoid-focused businesses puts pressure on market share and profitability. Limited financial resources and access to capital constrain the company's ability to fund research, development, and commercialization efforts. Negative perceptions of cannabis among some consumers could limit market acceptance of its products. Delays in clinical trials or regulatory approvals could significantly impact the company's timeline and financial prospects.
How does The Greater Cannabis Company, Inc. navigate regulatory approval processes?
Given that The Greater Cannabis Company, Inc. is focused on cannabinoid therapeutics, navigating regulatory approval processes is critical. The company must comply with FDA regulations for drug development and approval, including conducting clinical trials to demonstrate safety and efficacy. The regulatory pathway for cannabinoid-based drugs is still evolving, requiring the company to stay informed and adapt to changing requirements. Successful navigation of these processes is essential for commercializing its products and generating revenue. The company's ability to secure regulatory approvals will significantly impact its long-term success.
What are the key factors to evaluate for GCAN?
The Greater Cannabis Company, Inc. (GCAN) currently holds an AI score of 49/100, indicating low score. Key strength: Innovative oral transmucosal patch platform.. Primary risk to monitor: Potential: Evolving regulatory landscape for cannabis products.. This is not financial advice.
How frequently does GCAN data refresh on this page?
GCAN prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GCAN's recent stock price performance?
Recent price movement in The Greater Cannabis Company, Inc. (GCAN) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative oral transmucosal patch platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider GCAN overvalued or undervalued right now?
Determining whether The Greater Cannabis Company, Inc. (GCAN) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying GCAN?
Before investing in The Greater Cannabis Company, Inc. (GCAN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- OTC listing indicates higher risk and lower transparency.